Pharmacogenomics of cytarabine in childhood leukemia

Pharmacogenomics

Volumn 12, Issue 12, 2011, Pages 1629-1632

  Lamba, Jatinder K ^a  

^a PUMA Institute of Personalized Medicine   (United States)

Author keywords

acute myeloid leukemia; cytarabine; cytidine deaminase; deoxycytidine kinase; nucleoside transporter; pharmacogenetics

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYTARABINE; CYTIDINE DEAMINASE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; G PROTEIN COUPLED RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RIBONUCLEOTIDE REDUCTASE;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CDA GENE; CHILDHOOD LEUKEMIA; CMPK GENE; CTPS GENE; DCK GENE; DCTD GENE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; DRUG UPTAKE; FKBP5 GENE; GCAT GENE; GENE; GENETIC VARIABILITY; GIT1 GENE; HENT1 GENE; HUMAN; MYBBP1A GENE; NT5C2 GENE; NT5C3 GENE; PHARMACOGENOMICS; RAD51 GENE; REVIEW; RRM1 GENE; RRM2 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLC25A37 GENE; STEM CELL TRANSPLANTATION; TLE4 GENE; ZNF278 GENE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BIOMARKERS, PHARMACOLOGICAL; CHILD; CHILD, PRESCHOOL; CYTARABINE; DEOXYCYTIDINE KINASE; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC VARIATION; HUMANS; INFANT; LEUKEMIA, MYELOID, ACUTE; SIGNAL TRANSDUCTION;

EID: 82255193086     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.148     Document Type: Review

References (22)

1. Capizzi RL, Yang JL, Cheng E et al. Alteration of the pharmacokinetics of highdose araC by its metabolite, high araU in patients with acute leukemia. J. Clin. Oncol. 1, 763-771 (1983). (Pubitemid 14167250)
2. Kufe DW, Major PP, Egan EM, Beardsley GP. Correlation of cytotoxicity with incorporation of araC into DNA. J. Biol. Chem. 255, 8997-8900 (1980).
3. Major PP, Egan EM, Beardsley GP, MindenMD, Kufe DW. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl Acad. Sci. USA 78, 3235-3239 (1981). (Pubitemid 11032022)
4. Raza A, Gezer S, Anderson J et al. Relationship of [3H]araC incorporation and response to therapy with highdose araC in AML patients: a Leukemia Intergroup study. Exp. Hematol. 20, 1194-1200 (1992).
5. Kufe, DW, Munroe D, Herrick D, Egan E, Spriggs D. Effects of 1betaDarabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol. Pharmacol. 26, 128-134 (1984). (Pubitemid 14035234)
6. Chou TC, Arlin Z, Clarkson BD, Phillips FS. Metabolism of 1betaDarabinofuranosylcytosine in human leukemic cells. Cancer Res. 37, 3561-3570 (1977). (Pubitemid 8198413)
7. Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed araC therapy for refractory leukemia. Semin. Oncol. 12, 20-30 (1985). (Pubitemid 15063578)
8. Lamba JK. Genetic factors influencing cytarabine therapy. Pharmacogenomics 10 (10), 1657-1674 (2009).
9. Shi JY, Shi ZZ, Zhang SJ et al. Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14, 759-768 (2004).
10. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, Schellens JH. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur. J. Clin. Pharmacol. 62, 681-684 (2006). (Pubitemid 44127999)
11. Lamba JK, Crews K, Pounds S et al. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther. 323, 935-945 (2007). (Pubitemid 350146062)
12. Yue L, Saikawa Y, Ota K et al. A functional singlenucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13, 29-38 (2003). (Pubitemid 36135684)
13. Yonemori K, Ueno H, Okusaka T et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin. Cancer Res. 11, 2620-2624 (2005). (Pubitemid 40569462)
14. Bhatla D, Gerbing RB, Alonzo TA et al. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br. J. Haematol. 144, 388-394 (2009).
15. Mahlknecht U, Dransfeld CL, Bulut N et al. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C451T as an independent prognostic parameter for survival. Leukemia 23 (10), 1929-1932 (2009).
16. Aksoy P, Zhu MJ, Kalari KR et al. Cytosolic 5́nucleotidaseIII (NT5C3): gene sequence variation and functional genomics. Pharmacogenet. Genomics 19 (8), 567-576 (2009).
17. Mitra AK, Crews KR, Pounds S et al. Genetic variants in cytosolic 5́nucleotidaseII are associated with its expression and cytarabine sensitivity in HapMap Cell lines and in patients with acute myeloid leukemia. J. Pharmacol. Exp. Ther. 339 (1), 9-23 (2011).
18. Mitra AK, Crews K, Pounds S et al. Impact of genetic variation in FKBP5 on clinical response in pediatric acute myeloid leukemia patients: a pilot study. Leukemia 25 (8), 1354-1356 (2011).
19. Hartford CM, Duan S, Delaney SM et al. Populationspecific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113, 2145-2153 (2009).
20. Li L, Fridley B, Kalari K et al. Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression. Cancer Res. 68, 7050-7058 (2008).
21. Pei H, Li L, Fridley BL et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16, 259-266 (2009).
22. Lamba JK, Crews KR, Pounds SB et al. Identification of predictive markers of cytarabine response in AML by integrative analysis of geneexpression profiles with multiple phenotypes. Pharmacogenomics 12 (3), 327-339 (2011).